Exelixis, Inc. — Form 10-Q Summary
Period clarification: The request identifies 2022 Q2, but the supplied filing is for the quarter and six months ended June 30, 2023, with comparisons to 2022. Filed August 1, 2023.
Business context
Exelixis is an oncology company with four marketed products. CABOMETYX, its principal product, generates most revenue; other products include COMETRIQ, COTELLIC and MINNEBRO. The company is advancing cabozantinib indications and pipeline candidates, notably zanzalintinib and the XB002 antibody-drug conjugate.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Change |
|---|---|---|---|
| Total revenue | $469.8 million | $419.4 million | +12% |
| Net product revenue | $409.6 million | $347.0 million | +18% |
| Operating income | $77.9 million | $83.7 million | -7% |
| Net income | $81.2 million | $70.7 million | +15% |
| Diluted EPS | $0.25 | $0.22 | — |
| Operating margin | 16.6% | 20.0% | — |
| Net margin | 17.3% | 16.9% | — |
For the six months, revenue rose 13% to $878.6 million, while operating income fell 36% to $106.7 million and net income fell 13% to $121.2 million. Six-month diluted EPS was $0.37 versus $0.43.
- Q2 CABOMETYX revenue increased 19% to $403.3 million. Management attributed product growth mainly to 10% more units sold, reflecting the first-line RCC combination with OPDIVO and market-share gains, and a 9% increase in average net selling price.
- Q2 R&D expense rose 17% to $232.6 million; SG&A rose 15% to $141.7 million. Higher development, manufacturing, personnel, technology and legal/advisory costs contributed. Cost of goods sold increased 31% to $17.7 million; reported gross margin remained 96%.
- Interest income rose to $22.5 million from $4.8 million, primarily reflecting higher interest rates and investment balances.
Cash, liquidity and capital allocation
At June 30, cash, cash equivalents and investments totaled $2.105 billion, up from $2.067 billion at year-end 2022. Working capital was $1.251 billion. Cash and investments included $464.5 million of cash and equivalents and $1.641 billion of short- and long-term investments. The balance sheet reports no debt; liabilities include operating lease obligations. Management said available funds and expected operating receipts should support operations for at least 12 months and thereafter for the foreseeable future.
Six-month operating cash flow was $205.4 million, compared with $178.8 million in 2022. Investing used $123.4 million; financing used $120.2 million, including $124.2 million of share repurchases. The company repurchased 6.6 million shares for approximately $127 million and had about $423 million remaining under its $550 million authorization.
Changes, outlook and material risks
- Revenue growth was led by CABOMETYX, while collaboration services revenue fell 50% in Q2 to $7.5 million, mainly reflecting lower development cost reimbursements. License revenue declined 8% to $52.7 million.
- Management expected net product revenue to increase for the remainder of 2023, but collaboration services revenue could decline and R&D and SG&A expenses could rise. No specific full-year revenue or earnings guidance is provided in the supplied text.
- R&D included a $35 million milestone payment to Sairopa for ADU-1805; the company also reported $37.5 million of acquired in-process R&D technology expense for the first half. Potential future in-licensing milestones are substantial, including up to $634.1 million development, $625.4 million regulatory and $3.1 billion commercial milestones, plus royalties.
- COSMIC-313 met its primary PFS endpoint, but the interim OS analysis showed no significant benefit; another OS analysis was expected in the second half of 2023. CONTACT-01 and CONTACT-03 did not meet their primary endpoints. CONTACT-02 primary PFS results were expected in the second half of 2023.
- Generic competition is a key CABOMETYX risk. A July 2023 Teva settlement, subsequent to quarter-end, provides for a U.S. generic license beginning January 1, 2031, if FDA-approved and subject to conditions. MSN II litigation remained pending, with trial scheduled for October 2023; Cipla litigation was stayed. The filing says an early generic launch could materially harm revenue and results.
- Other risks include drug-price regulation and reimbursement pressure, clinical and regulatory uncertainty, reliance on third-party manufacturing and supply, and the ability to sustain CABOMETYX commercial performance. The company anticipated higher 2023 federal tax payments from required capitalization of R&D expenditures.
Investor verification checklist
- Confirm the intended reporting period: the supplied filing covers Q2 2023, not Q2 2022.
- Track CABOMETYX sales drivers, discounts and rebates, and the trend in collaboration revenue and reimbursements.
- Monitor R&D spending and clinical milestones, especially zanzalintinib, XB002 and cabozantinib trial results.
- Review developments in MSN and Cipla patent cases and the terms and practical implications of the Teva settlement.
- Check cash generation, investment balances, planned spending, tax payments and remaining share-repurchase activity.